[kml_flashembed movie="/wp-content/themes/rockinpaper-3col-1/images/1675_3.swf" height="102" width="190" /]

About tradingpattern.ch

The movement of a security's price over a specific time period.

dedicated to value creation and applying the scientific method in finance

Search


www.brokerbase.ch network - market statistics - weekly update

www.brokerbase.ch High dividend yield stocks

www.brokerbase.ch network

www.brokerbase.ch network - archived market statistics

Blogroll


Recent Posts

Blogs Bloggeramt.de Deutsches Blog Verzeichnis Add to Google

Novartis

« Previous Entries

Novartis erhoeht trotz Gewinnrueckgang Prognose

Tuesday, October 29th, 2013

Novartis hat womoeglich japanisches Recht verletzt – Experten

Tuesday, October 29th, 2013

Novartis-Tochter Alcon soll in China Aerzte bestochen haben

Tuesday, October 29th, 2013

AKTIEN SCHWEIZ/Verlauf: Knapp gehalten dank Novartis UBS floppen

Tuesday, October 29th, 2013

Novartis ist die Nummer eins

Tuesday, October 29th, 2013

Novartis erhoeht nach starkem Quartal die Jahresprognose

Wednesday, July 17th, 2013

Novartis and Biological E agree to deliver affordable vaccines for typhoid and paratyphoid A fevers to developing world

Monday, July 8th, 2013

Novartis-Mittel Lucentis erhaelt neue Indikation in der EU

Friday, July 5th, 2013

Novartis drug Lucentis approved in EU as first effective anti-VEGF treatment for myopic choroidal neovascularization

Friday, July 5th, 2013

Novartis reports new Phase III data showing omalizumab significantly improves itch in patients with severe form of chronic s

Wednesday, June 26th, 2013

Novartis – Sandoz launches Phase III clinical trial for biosimilar etanercept

Monday, June 24th, 2013

FDA grants Breakthrough Therapy designation to Novartis serelaxin (RLX030) for acute heart failure

Friday, June 21st, 2013

III Studienergebnisse zu Jakavi

Sunday, June 16th, 2013

Novartis drug Jakavi(R) improved overall survival of myelofibrosis patients and impacted an underlying mechanism of disease

Sunday, June 16th, 2013

Novartis konzentriert ihre Schweizer Geschäftseinheiten in Rotkreuz

Friday, June 14th, 2013

Novartis/Questcor erwirbt Rechte an Synacthen fuer 60 Mio USD Weitere Zahlungen

Tuesday, June 11th, 2013

Switching to Novartis drug Gilenya from standard interferon shown to improve long-term outcomes for patients with multiple s

Monday, June 10th, 2013

New data at ENS show Novartis drug Gilenya benefited patients by improving all four key measures of multiple sclerosis

Wednesday, June 5th, 2013

Novartis Breakthrough Therapy LDK378 shows a marked clinical response in patients with ALK+ non small cell lung cancer

Monday, June 3rd, 2013

Novartis Breakthrough Therapy 2

Monday, June 3rd, 2013

Positive Studiendaten fuer neuartiges Lungenkrebs Medikament LDK378

Monday, June 3rd, 2013

Positive Studiendaten fuer Lungenkrebs Medikament

Monday, June 3rd, 2013

Novartis Breakthrough Therapy LDK378 shows a marked clinical response in patients with ALK+ non-small cell lung cancer

Monday, June 3rd, 2013

Novartis pivotal Phase III trial shows Afinitor(R) significantly delays tumor growth in HER2 positive advanced breast cancer

Sunday, June 2nd, 2013

Novartis und Dietmar Hopp pruefen Verkauf von Tochter LTS – Kreise

Friday, May 31st, 2013

Novartis – Lucentis(R) receives positive opinion for patients with myopic choroidal neovascularization showing vision gains w

Friday, May 31st, 2013

Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO

Thursday, May 30th, 2013

Novartis legt Galvus Daten fuer individualisierte Diabetes 2 Therapie vor

Friday, May 24th, 2013

Key vildagliptin data in The Lancet show for the first time individualized HbA1c treatment goals can be reached in elderly type 2 di…

Thursday, May 23rd, 2013

Key vildagliptin data in 2

Thursday, May 23rd, 2013

Novartis – Key vildagliptin data in The Lancet show for the first time individualized HbA1c treatment goals can be reached in

Thursday, May 23rd, 2013

Largest ever global survey of 1,273 women in 12 countries reveals women with advanced breast cancer feel left out of the breast canc…

Tuesday, May 21st, 2013

Largest ever global 2

Tuesday, May 21st, 2013

Neue Studiendaten belegen Wirkung von COPD Franchise

Tuesday, May 21st, 2013

New data reinforces strength of Novartis once daily COPD portfolio in improving lung function, shortness of breath and reducing rate of exacer…

Tuesday, May 21st, 2013

New data reinforces strength of Novartis once-daily COPD portfolio in improving lung function, shortness of breath and reduc

Tuesday, May 21st, 2013

ever global survey of 1,273 women in 12 countries reveals women with advanced breast cancer feel left out

Tuesday, May 21st, 2013

Novartis erhaelt “Business Action on Health Award” von GBC Health fuer Sozialprojekt

Friday, May 17th, 2013

Thomson Reuters ONE/Novartis erhaelt “Business Action on Health Award” von GBC Health fuer Sozialprojekt

Friday, May 17th, 2013

Positive Phase III Studiendaten zu Afinitor (Everolimus)

Friday, May 17th, 2013 « Previous Entries